Yahoo Web Search

Search results

1. • 

     New drug therapy ‘highly effective’ for young children with severe eczema

     Press Association News via AOL· 2 years ago

     A new drug therapy to treat moderate to severe eczema in young children has been shown to be “safe...

2. • 

     Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag

     Zacks via Yahoo Finance· 2 years ago

     Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental...

3. • 

     Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

     Zacks via Yahoo Finance· 2 years ago

     Sanofi SNY and its partner Regeneron REGN recently announced that the FDA has approved their...

4. • 

     ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients

     Benzinga via Yahoo Finance· 2 years ago

     ASLAN Pharmaceuticals (NASDAQ: ASLN) plans to initiate a new clinical trial of eblasakimab for...

5. • 

     UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent

     Benzinga via Yahoo Finance· 1 year ago

     The UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related...

6. • 

     Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis

     Benzinga via Yahoo Finance· 1 year ago

     The European Commission approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's...

7. • 

     The Most Exciting New Advances in Managing COPD

     Time via Yahoo News· 2 months ago

     Credit - Karl Tapales—Getty Images The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, is the world’s preeminent COPD research and...

8. • 

     Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years

     Benzinga via Yahoo Finance· 2 years ago

     Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent...

9. • 

     Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

     Zacks via Yahoo Finance· 1 year ago

     This week, Eli Lilly’s LLY candidate, solanezumab, failed to prevent Alzheimer’s in a study. Merck’s...

10. • 

      Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

      Benzinga via Yahoo Finance· 2 years ago

      The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent...